Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-049 in Relapsed/Refractory AML or MDS
NCT05143996Phase 2Recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cln-049 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Number of treatment emergent events at 28 days, Maximum observed concentration of CLN-049 up to 13 weeks and 4 more. Started Nov 2021; status: recruiting.
02
Drugs
cln-049
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05143996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143996.